This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
330
oral, once daily until sponsor stopped the study
safety of azimilide in this patient population
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Facility
Mobile, Alabama, United States
Research Facility
Little Rock, Arkansas, United States
Research Facility
La Jolla, California, United States
Research Facility
Loma Linda, California, United States
Research Facility
Sacramento, California, United States
Research Facility
Colorado Springs, Colorado, United States
Research Facility
Bridgeport, Connecticut, United States
Research Facility
Washington D.C., District of Columbia, United States
Research Facility
Fort Lauderdale, Florida, United States
Research Facility
Fort Myers, Florida, United States
...and 76 more locations